tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IMRX Stock Latest News

Immuneering Announces Public Offering to Raise $164.1M
Company AnnouncementsImmuneering Announces Public Offering to Raise $164.1M
2d ago
8K
IMRX
Immuneering price target raised to $30 from $21 at Oppenheimer
PremiumThe Fly
Immuneering price target raised to $30 from $21 at Oppenheimer
2d ago
IMRX
Immuneering 18.96M share Spot Secondary priced at $9.23
PremiumThe Fly
Immuneering 18.96M share Spot Secondary priced at $9.23
2d ago
IMRX
Promising Clinical Trial Results and Favorable Safety Profile Support Buy Rating for Immuneering
PremiumRatings
Promising Clinical Trial Results and Favorable Safety Profile Support Buy Rating for Immuneering
2d ago
IMRX
Immuneering Announces $25M Securities Purchase Agreement
PremiumCompany Announcements
Immuneering Announces $25M Securities Purchase Agreement
2d ago
8K
IMRX
Immuneering announces data from trial of atebimetinib combination
PremiumThe FlyImmuneering announces data from trial of atebimetinib combination
3d ago
IMRX
Immuneering announces Class A common stock offering, private placement
Premium
The Fly
Immuneering announces Class A common stock offering, private placement
3d ago
IMRX
Immuneering appoints Schall as Chairman of the Board
Premium
The Fly
Immuneering appoints Schall as Chairman of the Board
11d ago
IMRX
Immuneering’s Strategic Advances and Positive Outlook Boost Buy Rating and Price Target
PremiumRatings
Immuneering’s Strategic Advances and Positive Outlook Boost Buy Rating and Price Target
12d ago
IMRX
Immuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnP
PremiumThe Fly
Immuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnP
17d ago
IMRX
Immuneering files to sell 9.18M shares of Class A common stock for holders
PremiumThe Fly
Immuneering files to sell 9.18M shares of Class A common stock for holders
24d ago
IMRX
Immuneering’s Strategic Partnerships and Promising Clinical Developments Justify Buy Rating
PremiumRatings
Immuneering’s Strategic Partnerships and Promising Clinical Developments Justify Buy Rating
1M ago
IMRX
Immuneering announces clinical supply agreement with Eli Lilly
PremiumThe FlyImmuneering announces clinical supply agreement with Eli Lilly
1M ago
LLY
IMRX
Immuneering prices 6.3M shares at $3.95 in private placement
Premium
The Fly
Immuneering prices 6.3M shares at $3.95 in private placement
1M ago
IMRX
Immuneering Corp. Reports Strong Trial Results and Patent Win
Premium
Company Announcements
Immuneering Corp. Reports Strong Trial Results and Patent Win
1M ago
IMRX
Immuneering files $300M mixed securities shelf
PremiumThe Fly
Immuneering files $300M mixed securities shelf
1M ago
IMRX
Immuneering reports Q2 EPS (40c), consensus (40c)
PremiumThe Fly
Immuneering reports Q2 EPS (40c), consensus (40c)
1M ago
IMRX
Immuneering granted atebimetinib patent by USPTO
PremiumThe Fly
Immuneering granted atebimetinib patent by USPTO
3M ago
IMRX
Immuneering price target raised to $10 from $8 at Mizuho
PremiumThe Fly
Immuneering price target raised to $10 from $8 at Mizuho
3M ago
IMRX
Immuneering’s Promising Clinical Developments and Future Prospects Justify Buy Rating
PremiumRatingsImmuneering’s Promising Clinical Developments and Future Prospects Justify Buy Rating
3M ago
IMRX
Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly
Premium
The Fly
Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly
3M ago
DYN
JBL
Immuneering Announces Promising Phase 2a Trial Results
Premium
Company Announcements
Immuneering Announces Promising Phase 2a Trial Results
3M ago
8K
IMRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >